Inovio Pharmaceuticals, Inc. announced that Mr. Shawn D. Bridy joins the company as Vice President of Business Development reporting to Dr. J. Joseph Kim, President & CEO. Mr. Bridy has more than 20 years of business development & licensing, commercial strategy, and transaction experience in the life sciences industry. He previously held strategic business development roles at large pharma companies and smaller biotechs including GSK, Elan, BTG plc and Immunome. Most recently he was Managing Director of Bridy Advisors. Inovio has also promoted Dr. Kate E. Broderick, Ph.D., to Vice President, Preclinical Research & Development reporting to Dr. Laurent Humeau, Senior Vice President, R&D. In her new position, Dr. Broderick will continue to spearhead Inovio's efforts to secure non-dilutive strategic R&D funding opportunities to support the research and clinical testing of Inovio's candidate vaccines. Dr. Broderick has previously led Inovio's efforts to receive numerous grants from the U.S. National Institutes of Health and Department of Defense as well from other government and non-governmental organizations. She recently led Inovio's efforts to secure a $56 million funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to evaluate DNA vaccine candidates for Lassa fever and MERS through Phase 2 clinical testing. She will also be responsible for the oversight of a diverse preclinical R&D team encompassing discovery and development research, as well as operations, research DNA manufacturing and next-generation device development.